Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 21
---
86%, were non progressors, including all
with an intact colon; of these, 15 out of 29 patients, or 67%, demonstrated PR, including four with an intact colon. Only two drug-related
Grade 3 serious adverse events, or SAEs, occurred during the trial (with no Grade 4 or 5 SAEs reported), and 97% of patients remained
on treatment at six months. In summary, after six months’ treatment, eRapa appeared safe and well-tolerated with a significant 24%
reduction in the total polyp burden at six months compared with baseline (p=0.04) and an overall 83% non-progression rate.

On June 24,
2024, we announced 12 month results of the Phase 2 clinical trial which were presented at the 2024 InSIGHT bi-annual meeting in Barcelona.
Overall, 21 out of 28 patients, or 75%, were deemed to be non-progressors at 12 months, with a median reduction in polyp burden of 17%.
Over the course of 12 months, there were four related Grade 3 or higher and one related SAE reported during the trial, and a 95% compliance
rate at 12 months. One patient was removed from the trial due to non-compliance. In summary, after 12 months’ treatment, eRapa appeared
safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progression
rate. The 89% non-progression rate and 29% median reduction in polyp burden in Cohort 2 is likely to be the preferred dosage regimen for
Phase 3.

| 8 |

Tolimidone Developments

On July 16, 2024, we announced Health Canada had
approved a Phase 2a dose confirmation trial of tolimidone in T1D. The study is an Investigator Initiated Trial to be conducted by the
University of Alberta. The trial will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three
months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The trial may
be expanded in due course.

MTX110 Developments

On October 4, 2024, we announced